An interventional study of biopsy in Gastrointestinal Cancer and IBD, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Other
Among 63 studies in Gastrointestinal Neoplasms with a site in France — 27 open to participants now, 32 under way, 3 of them phase 3. Gastrointestinal Neoplasms · France.
Among the 63 studies in Gastrointestinal Neoplasms with a site in France, this one is the 18th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2026, is one of 23 with no phase, reaches primary completion later than 5 of the 31 other live ones, and was the 55th registered.
695 studies on the registry are indexed under Gastrointestinal Neoplasms; 209 are open to participants now.
Browse Gastrointestinal Neoplasms studies →27 of the 63 studies in Gastrointestinal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Genmab · Sites in France, United States, Australia and 8 more countries
Pfizer · Sites in France, United States, Argentina and 14 more countries
GlaxoSmithKline · Sites in France, United States, Australia and 16 more countries
Verastem, Inc. · Sites in France, United States, Australia and 1 more country
GlaxoSmithKline · Sites in France, United States, Australia and 16 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 9
First in 2004; this study’s year is marked. 7 started in 2026.
This study's planned enrollment of 400 is above the median of 74 across 494 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 200 across the 51 interventional studies, 131 across the 10 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 63 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
University Hospital, Strasbourg, France has 2 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Gastrointestinal Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07575854Centre Georges Francois LeclercA Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer | 2026-12-01 |
| NCT07782203University Hospital, Strasbourg, FranceEstablishment of a Biological Collection to Develop Translational Preclinical Models for the Study of Tumors and Diseases of the Gastrointestinal Tract | 2026-12-30 |
| NCT04268121GERCOR - Multidisciplinary Oncology Cooperative GroupEfficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | 2027-01 |
| NCT05994521McGill University Health Centre/Research Institute of the McGill University Health CentreProphylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers | 2027-02 |
| NCT06881303Assistance Publique Hopitaux De MarseilleImpact of Prior Identification and Education of Patients Requiring a Digestive Stoma for Fecal Diversion | 2027-03-01 |
Among the 63 studies in Gastrointestinal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The causes underlying the development of chronic inflammatory bowel diseases (IBD) and digestive cancers remain poorly understood. They involve both genetic susceptibilities and multiple environmental factors.
Research and the development of new therapeutic strategies are essential to provide patients with novel treatment opportunities. A deep understanding of the tumor ecosystem at the molecular level, as well as the interactions between different cell types, is crucial to identify and validate new therapeutic targets.
Since animal cancer models have shown their limitations in translating results to humans, studies models are often based on autologous patient tissues and sera. These innovative models make it possible to:
This work has led to numerous publications on advanced digestive cancers, such as those of the liver or the bile acid pathway To create ex vivo models and reconstruct the tumor in vitro, experiments require treating tumor cells with blood from the same patient (autologous), collected simultaneously with the tumor resection. The tumor tissues used in culture are obtained from residual material of anatomopathological analyses performed as part of clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients for whom gastrointestinal surgery is indicated in the context of IBD or suspected gastrointestinal cancer (esophagus, stomach, colon/rectum
Procedure: biopsy
Patients for whom gastrointestinal endoscopy is planned in the context of suspected or follow-up of IBD
Procedure: biopsy
Patients for whom gastrointestinal endoscopy is planned in the context of suspected gastrointestinal cancer
Procedure: biopsy
collect tissues and blood cell
Number of tissue samples suitable for cell culture procedures
Number of tissue samples collected from eligible participants during routine surgical procedures or digestive endoscopy and considered suitable for the cell culture procedures defined in the study protocol. The collected tissue samples will contribute to a biological collection intended for fundamental research on the development of tumors and diseases of the gastrointestinal tract.
Time frame: At the time of surgery or digestive endoscopy
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 153 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 9 months is below that.
Counting every sponsor, half of 163 studies reached it within 35 months; a quarter within 17 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →